The Tilburg Vasospasm Study

August 1, 2011 updated by: Elisabeth-TweeSteden Ziekenhuis

Prevention of Secondary Ischemia After Aneurysmal Subarachnoid Hemorrhage With Cerebrospinal Fluid Drainage. A Randomized Controlled Trial

In a prospective randomized controlled trial, the investigators aim to assess whether external lumbar drainage (ELD) of CSF is safe and reduces delayed cerebral ischemia and its sequelae in patients with an aneurysmal subarachnoid hemorrhage.

Study Overview

Detailed Description

Delayed cerebral ischemia (DCI) is a frequent complication after an aneurysmal subarachnoid hemorrhage (SAH). Its pathophysiological mechanism remains unclear but a role for cerebral vasospasm and the presence of blood in the arachnoid space is likely. A wash out of blood and blood breakdown products in the cerebrospinal fluid (CSF) could reduce the incidence of vasospasm and DCI.

We aim to assess whether external lumbar drainage (ELD) of CSF is safe and reduces secondary ischemia and its sequelae.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Brabant
      • Tilburg, Brabant, Netherlands, 5022 GC
        • St Elisabeth Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • spontaneous subarachnoid hemorrhage (SAH) with aneurysmal pattern graded as a Fisher grade III or higher on cerebral CT-scan.
  • CSF drainage by external lumbar catheter can start within 96 hours after the initial SAH
  • the drainage can start prior to the treatment of the ruptured aneurysm
  • informed consent is signed by the patient or his representative

Exclusion Criteria:

  • spontaneous SAH with aneurysmal pattern graded as a Fisher grade I or II on CT and perimesencephalic hemorrhages
  • traumatic SAH
  • symptomatic hydrocephalus on admission necessitating drainage (EVD or ELD)
  • the presence of a large intraventricular bloodclot in the third or fourth ventricle on CT
  • the presence of a mass lesion with significant cerebral midline shift
  • all patients whose neurological condition is too poor to allow clinical recognition of signs and symptoms of cerebral vasospasm. This includes all patients with a Hunt and Hess Grade V who failed to improve after initial resuscitation
  • no informed consent
  • mycotic aneurysms

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: external lumbar drainage
Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
No Intervention: No intervention
In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical signs of delayed cerebral ischemia
Time Frame: Patients will be followed for the duration of admission, an expected average of 3 weeks
DCI was diagnosed when all of the following criteria were met: (1) the onset of new neurological deficits such as confusion, disorientation, drowsiness, or focal deficit during post-hemorrhage days (4 to 14); (2) negative findings on CT obtained to rule out other causes of neurological deterioration such as hemorrhage, cerebral edema, or hydrocephalus. (3) No other identifiable cause of neurological deterioration such as hyponatriemia, hypoxia, drug toxicity, infection, or seizures.
Patients will be followed for the duration of admission, an expected average of 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
dichotomized Glasgow outcome score (GOS)
Time Frame: at discharge, an expected average of 3 weeks after initial bleeding
Glasgow outcome scale was measured at discharge
at discharge, an expected average of 3 weeks after initial bleeding
new ischemic lesions on cerebral CT scan
Time Frame: at 3 months after initial bleeding
at 3 months after initial bleeding
length of stay in intensive care unit
Time Frame: Patients will be followed from initial admission until discharge, an expected average of 3 weeks
The length of stay in the intensive care unit will be measured.
Patients will be followed from initial admission until discharge, an expected average of 3 weeks
rebleeding rate of unsecured aneurysms and complications of external lumbar drainage
Time Frame: Patients willl be followed from initial bleeding until treatment of aneurysm, an expected average of 3 days
Evaluation of rebleeding rate of unsecured cerebral aneurysms during external lumbar drainage (ELD) of cerebrospinal fluid and evaluation of (other) complications of ELD such as (local)infection, discomfort/pain.
Patients willl be followed from initial bleeding until treatment of aneurysm, an expected average of 3 days
dichotomized Glasgow outcome score (GOS
Time Frame: at 3 months after initial bleeding
at 3 months after initial bleeding
clinical signs of delayed cerebral ischemia
Time Frame: At 3 months after initial bleeding
As stated in first primary outcome measure 'clinical signs of cerebral ischemia' during admission.
At 3 months after initial bleeding

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paul Depauw, MD, Elisabeth-TweeSteden Ziekenhuis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2007

Primary Completion (Actual)

March 1, 2009

Study Completion (Actual)

June 1, 2009

Study Registration Dates

First Submitted

January 10, 2011

First Submitted That Met QC Criteria

August 1, 2011

First Posted (Estimate)

August 2, 2011

Study Record Updates

Last Update Posted (Estimate)

August 2, 2011

Last Update Submitted That Met QC Criteria

August 1, 2011

Last Verified

August 1, 2011

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Ischemia

Clinical Trials on external lumbar drainage (ELD) of cerebrospinal fluid

3
Subscribe